Search Results - paul+sieving

3 Results Sort By:
RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS). This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition...
Published: 6/24/2026   |   Updated: 6/24/2026   |   Inventor(s): Paul Sieving, Yong Zeng, Ronald Bush
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases. This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1),...
Published: 6/18/2026   |   Updated: 6/16/2026   |   Inventor(s): Paul Sieving, Alaknanda MIshra, Vijayasarathy Camasamudram, Lisa Wei
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Ophthalmology, TherapeuticArea > Rare/Neglected Diseases
Methods and Compositions for Treating Genetically Linked Diseases of the Eye
Abstract: X-linked retinoschisis (XLRS) is an inherited, monogenetic ocular disease caused by mutations in the retinoschisin (RS1) gene, resulting in the development of cystic cavities throughout the retina and leading to juvenile macular degeneration. Approximately 1:15,000 males in the US are affected, classifying the condition as an orphan indication.  The...
Published: 5/15/2025   |   Updated: 8/2/2023   |   Inventor(s): Paul Sieving, Ronald Bush, Yong Zeng, Peter Colosi
Keywords(s): Clinical, EYE, GENE THERAPY, ophthalmological, Orphan Indication, Sieving, XLRS
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology